CA
CLDX icon

Cliff Asness’s Celldex Therapeutics CLDX Stock Holding History

Cliff Asness’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.23M Buy
86,893
+79,116
+1,017% +$2.56M ﹤0.01% 2294
2026
Q1 		$247K Buy
+7,777
New +$212K ﹤0.01% 3506
2025
Q1 		– Sell
-21,724
Closed -$549K – 3160
2024
Q4 		$549K Sell
21,724
-3,619
-14% -$98.3K ﹤0.01% 2204
2024
Q3 		$861K Buy
25,343
+17,486
+223% +$666K ﹤0.01% 1916
2024
Q2 		$291K Buy
7,857
+1,504
+24% +$56.7K ﹤0.01% 2282
2024
Q1 		$267K Buy
+6,353
New +$261K ﹤0.01% 2167
2023
Q3 		– Sell
-6,835
Closed -$232K – 2324
2023
Q2 		$232K Buy
6,835
+5
+0.1% +$169 ﹤0.01% 2037
2023
Q1 		$246K Sell
6,830
-1,738
-20% -$75K ﹤0.01% 1999
2022
Q4 		$382K Sell
8,568
-660
-7% -$23.6K ﹤0.01% 1908
2022
Q3 		$259K Sell
9,228
-232
-2% -$7.11K ﹤0.01% 1983
2022
Q2 		$255K Hold
9,460
– – ﹤0.01% 1916
2022
Q1 		$322K Hold
9,460
– – ﹤0.01% 1949
2021
Q4 		$366K Sell
9,460
-1,392
-13% -$60.7K ﹤0.01% 1924
2021
Q3 		$586K Buy
+10,852
New +$509K ﹤0.01% 1805
2016
Q1 		– Sell
-2,220
Closed -$523K – 2224
2015
Q4 		$523K Sell
2,220
-3,717
-63% -$810K ﹤0.01% 1857
2015
Q3 		$939K Sell
5,937
-1,656
-22% -$469K ﹤0.01% 1466
2015
Q2 		$2.87M Buy
7,593
+4,215
+125% +$1.67M 0.01% 1031
2015
Q1 		$1.41M Buy
3,378
+527
+18% +$189K ﹤0.01% 1266
2014
Q4 		$781K Buy
2,851
+364
+15% +$90.5K ﹤0.01% 1760
2014
Q3 		$483K Sell
2,487
-4,560
-65% -$994K ﹤0.01% 1950
2014
Q2 		$1.73M Buy
7,047
+4,137
+142% +$934K ﹤0.01% 1373
2014
Q1 		$771K Sell
2,910
-3,986
-58% -$1.53M ﹤0.01% 1818
2013
Q4 		$2.5M Buy
6,896
+2,515
+57% +$969K 0.01% 1222
2013
Q3 		$2.33M Sell
4,381
-1,120
-20% -$384K 0.01% 1197
2013
Q2 		$1.29M Buy
+5,501
New +$1.08M ﹤0.01% 1446

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cliff Asness's CLDX Position: Q2 2026 in Review

Cliff Asness increased its Celldex Therapeutics (CLDX) stake by 1,017% in Q2 2026, buying an estimated $2.56M and bringing the position to 86,893 shares worth $3.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2294.

Cliff Asness first reported a position in CLDX in Q2 2013 and has held it in 25 quarters since. 252 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Cliff Asness held 86,893 shares of Celldex Therapeutics worth $3.23M as of Q2 2026.
  • Cliff Asness bought 79,116 Celldex Therapeutics shares in Q2 2026, an estimated $2.56M.
  • Celldex Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2294 holding.
  • Cliff Asness first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 25 quarters since.
  • 252 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.